#United States #Radiotherapy #Stratford #XCELL TomoRad #KUBTEC Scientific

KUBTEC® Scientific Launches the XCELL® TomoRad™ for Cutting-Edge Radiotherapy Research

KUBTEC® Scientific, renowned for its pioneering role in X-ray imaging and irradiation, has officially introduced their latest innovation, the XCELL® TomoRad™ system. This product marks a significant advancement in the field of image-guided radiotherapy (IGRT), particularly designed for preclinical research.

The XCELL TomoRad system employs an innovative imaging technique known as tomosynthesis. This process captures numerous X-ray images from various angles, which are then utilized to construct a detailed three-dimensional view of the targeted area. This method presents considerable advantages over conventional microCT imaging, most notably in reducing radiation exposure for samples, accelerating image capture and reconstruction, and minimizing costs compared to traditional microCT systems.

Historically, IGRT systems have presented substantial hurdles due to their high costs and complicated installations, thus constraining access for many researchers. Responding to the demand for enhanced accessibility in IGRT, the KUBTEC Scientific team focused on developing a more user-friendly and economically viable option with their TomoRad system.

One of the system’s remarkable features is its Mag Mode™, a cutting-edge dose-delivery mechanism currently pending patent. This mode allows for the quick positioning of samples near the radiation tube, thereby providing maximum dosage in minimal time. For busy laboratories, this innovation promises to streamline treatment schedules, reducing the time required under anesthesia, and consequently lessening stress for the animal subjects involved.

Vikram Butani, CEO of KUBTEC Scientific, articulated the motivation behind the XCELL TomoRad's creation: "The entry barriers to image-guided radiation research have previously been formidable, stemming from slower imaging, complex treatment processes, and high costs associated with existing systems. Our discussions with researchers revealed the need for a balance between accurate targeting, operational efficiency, and simplicity in workflow. At KUBTEC, we are committed to creating preclinical technologies that empower researchers to advance their studies and ultimately improve clinical care. We believe the XCELL TomoRad will advance this mission, leading to less radiation exposure and quicker treatment cycles for patients."

Overall, the XCELL® TomoRad™ represents a transformative step in preclinical research, enabling more researchers to exploit the possibilities afforded by IGRT. KUBTEC’s dedication to innovation and accessibility in medical imaging and irradiation technology continues to set them apart in the industry. To learn more about the capabilities of the XCELL® TomoRad™ system, please visit their official website at www.kubtecscientific.com.

About KUBTEC® Scientific

Established over two decades ago, KUBTEC® Scientific is driven by the mission to advance transformative technologies in preclinical research. With a strong portfolio of X-ray imaging systems, they offer a comprehensive range of solutions tailored to tackle the critical question surrounding disease research. Their proprietary technologies and software not only facilitate research but support the development of modern healthcare solutions.